洁特生物(688026) - 2021 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders increased by 43.52% to CNY 48,051,641.98 year-on-year[6] - Operating revenue surged by 133.58% to CNY 173,974,009.06 compared to the same period last year[6] - Basic earnings per share increased by 29.73% to CNY 0.48[6] - The weighted average return on equity increased by 0.43 percentage points to 5.85%[6] - The net profit for Q1 2021 was RMB 54.71 million, representing a year-on-year growth of 213.50%[14] - Total operating revenue for Q1 2021 was RMB 174 million, up 133.58% compared to the same period last year[14] - The net profit for Q1 2021 reached RMB 54,714,438.52, up 213.5% from RMB 17,452,772.29 in Q1 2020[39] - The operating profit for Q1 2021 was RMB 63,859,274.49, representing a growth of 232.5% compared to RMB 19,246,908.58 in Q1 2020[37] Assets and Liabilities - Total assets increased by 10.17% to CNY 1,068,331,678.62 compared to the end of the previous year[6] - The company's current assets totaled CNY 637,279,399.47 as of March 31, 2021, compared to CNY 593,357,600.55 at the end of 2020, indicating an increase of about 7.4%[24] - Total liabilities as of March 31, 2021, were CNY 223,386,848.80, up from CNY 172,815,886.48, representing a growth of about 29.2%[26] - The company's equity attributable to shareholders increased to CNY 844,944,829.82 from CNY 796,893,187.84, reflecting an increase of approximately 6%[26] - Total assets as of Q1 2021 amounted to ¥1,020,522,784.75, up from ¥903,556,874.38 in the previous year, representing a growth of approximately 12.9%[30] - Total liabilities for Q1 2021 were ¥184,058,559.29, compared to ¥121,807,087.44 in Q1 2020, indicating an increase of about 51.0%[30] Cash Flow - The net cash flow from operating activities decreased by 101.63% to -CNY 1,228,119.17 compared to the previous year[6] - The cash flow from operating activities showed a net outflow of RMB 1,228,119.17 in Q1 2021, contrasting with a net inflow of RMB 75,427,925.93 in Q1 2020[40] - The total cash and cash equivalents at the end of Q1 2021 were RMB 247,614,375.00, down from RMB 490,703,028.03 at the end of Q1 2020[40] - The cash outflow from investing activities in Q1 2021 was RMB 54,054,106.13, compared to RMB 17,462,814.20 in Q1 2020[40] - Cash inflow from financing activities in Q1 2021 was RMB 393,275,943.40, while cash outflow was RMB 941,886.78, resulting in a net cash inflow of RMB 392,334,056.62[43] Research and Development - The proportion of R&D investment to operating revenue decreased by 0.38 percentage points to 2.74%[6] - The company's research and development expenses grew by 105.21% to RMB 4.78 million, reflecting ongoing investment in projects[15] - Research and development expenses for Q1 2021 were ¥4,775,140.09, compared to ¥2,326,976.91 in Q1 2020, indicating an increase of about 105.5%[33] Shareholder Information - The number of shareholders reached 6,418 at the end of the reporting period[10] - The top shareholder, Yuan Jianhua, holds 31.00% of the shares[11] Market and Product Development - The company is focused on expanding its market presence and developing new products and technologies[21] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[34] Legal and Compliance - The company faced a legal dispute involving a prepayment of RMB 20.31 million related to mask equipment contracts[18] - The implementation of the new leasing standard began on January 1, 2021, affecting the financial reporting of the company[53]